Genetic association of lipid-lowering drug target genes with pancreatic cancer: a Mendelian randomization study
Abstract Previous studies have found that dyslipidemia is a risk factor for pancreatic cancer (PC), and that lipid-lowering drugs may reduce the risk of PC. However, it is not clear whether dyslipidemia causes PC. The Mendelian randomization (MR) study aimed to investigate the causal role of lipid t...
Saved in:
Main Authors: | Bohan Su, Zhiyao Fan, Jiexi Wu, Hanxiang Zhan |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-87490-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Associations between lipid-lowering drugs and urate and gout outcomes: a Mendelian randomization study
by: Min Liu, et al.
Published: (2025-01-01) -
Insights Into Causal Effects of Genetically Proxied Lipids and Lipid‐Modifying Drug Targets on Cardiometabolic Diseases
by: Liwan Fu, et al.
Published: (2025-02-01) -
Investigating the role of cathepsins in breast cancer progression: a Mendelian randomization study
by: Shengyi Zhou, et al.
Published: (2025-01-01) -
Single-cell transcriptome-wide Mendelian randomization and colocalization reveals immune-mediated regulatory mechanisms and drug targets for COVID-19Research in context
by: Hui Ying, et al.
Published: (2025-03-01) -
Brain gliomas new transcriptomic discoveries from differentially expressed genes to therapeutic targets
by: Shiwen Pei, et al.
Published: (2025-01-01)